Omeros Co. (NASDAQ:OMER – Free Report) – Equities research analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Omeros in a research note issued to investors on Tuesday, June 10th. HC Wainwright analyst B. Folkes forecasts that the biopharmaceutical company will earn ($1.78) per share for the year. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.
OMER has been the topic of several other research reports. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Friday, June 6th. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, May 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.
Omeros Stock Down 1.9%
NASDAQ:OMER opened at $3.55 on Thursday. The business’s 50-day moving average price is $5.16 and its two-hundred day moving average price is $7.80. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The stock has a market cap of $208.01 million, a P/E ratio of -1.54 and a beta of 2.20.
Omeros (NASDAQ:OMER – Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05).
Institutional Trading of Omeros
Hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund lifted its holdings in shares of Omeros by 245.4% in the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 12,300 shares during the last quarter. US Bancorp DE bought a new stake in Omeros in the fourth quarter worth $81,000. Raymond James Financial Inc. bought a new stake in shares of Omeros in the 4th quarter valued at about $124,000. AlphaQuest LLC bought a new stake in shares of Omeros in the 4th quarter valued at about $285,000. Finally, Truvestments Capital LLC lifted its stake in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- How to Use the MarketBeat Excel Dividend Calculator
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- A Deeper Look at Bid-Ask Spreads
- 3 Stocks Set to Double—And There’s Still Time to Buy
- 3 Fintech Stocks With Good 2021 Prospects
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.